The objective of this study is to evaluate the safety and tolerability of multiple intravenous (IV) infusions of KHK4083 in subjects with moderate or severe atopic dermatitis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
26
IV administration
Closed information
Sapporo, Japan
Incidence of treatment-emergent adverse events (TEAEs) or drug-related TEAEs and their nature
Time frame: Up to 22 weeks post drug administration
Serum KHK4083 concentration
Time frame: Up to 22 weeks post drug administration
Maximum concentration (Cmax)
Time frame: Up to 22 weeks post drug administration
Time to reach Cmax (tmax)
Time frame: Up to 22 weeks post drug administration
Area under the curve (AUC)
Time frame: Up to 22 weeks post drug administration
Anti-KHK4083 antibody production
Time frame: Up to 22 weeks post drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.